98 related articles for article (PubMed ID: 26398647)
1. Overview of hemodialysis treatment funded by the Brazilian Unified Health System--An economic perspective.
Menezes FG; Barreto DV; Abreu RM; Roveda F; Pecoits Filho RF
J Bras Nefrol; 2015; 37(3):367-78. PubMed ID: 26398647
[TBL] [Abstract][Full Text] [Related]
2. Cost of chronic kidney disease attributable to diabetes from the perspective of the Brazilian Unified Health System.
Goncalves GMR; Silva END
PLoS One; 2018; 13(10):e0203992. PubMed ID: 30273345
[TBL] [Abstract][Full Text] [Related]
3. Dialysis care, cardiovascular disease, and costs in end-stage renal disease in Brazil.
Sesso R; da Silva CB; Kowalski SC; Manfredi SR; Canziani ME; Draibe SA; Elgazzar HA; Ferraz MB
Int J Technol Assess Health Care; 2007; 23(1):126-30. PubMed ID: 17234026
[TBL] [Abstract][Full Text] [Related]
4. Cluster analysis and its application to healthcare claims data: a study of end-stage renal disease patients who initiated hemodialysis.
Liao M; Li Y; Kianifard F; Obi E; Arcona S
BMC Nephrol; 2016 Mar; 17():25. PubMed ID: 26936756
[TBL] [Abstract][Full Text] [Related]
5. Economic evaluation of palliative management versus peritoneal dialysis and hemodialysis for end-stage renal disease: evidence for coverage decisions in Thailand.
Teerawattananon Y; Mugford M; Tangcharoensathien V
Value Health; 2007; 10(1):61-72. PubMed ID: 17261117
[TBL] [Abstract][Full Text] [Related]
6. The cost of hemodialysis in Iran.
Arefzadeh A; Lessanpezeshki M; Seifi S
Saudi J Kidney Dis Transpl; 2009 Mar; 20(2):307-11. PubMed ID: 19237828
[TBL] [Abstract][Full Text] [Related]
7. Cost analysis of substitutive renal therapies in children.
Camargo MFC; Barbosa KS; Fetter SK; Bastos A; Feltran LS; Koch-Nogueira PC
J Pediatr (Rio J); 2018; 94(1):93-99. PubMed ID: 28750890
[TBL] [Abstract][Full Text] [Related]
8. Cost calculations during "dire straits": a cost-of-illness analysis of regular hemodialysis for end-stage renal disease in Greece.
Naoum P; Topkaroglou I; Kitsonis D; Skroumpelos A; Athanasakis K; Iatrou C; Boletis J; Kyriopoulos J
Int J Artif Organs; 2016 Feb; 39(2):87-9. PubMed ID: 26953901
[TBL] [Abstract][Full Text] [Related]
9. Comparing VA and private sector healthcare costs for end-stage renal disease.
Hynes DM; Stroupe KT; Fischer MJ; Reda DJ; Manning W; Browning MM; Huo Z; Saban K; Kaufman JS;
Med Care; 2012 Feb; 50(2):161-70. PubMed ID: 21945972
[TBL] [Abstract][Full Text] [Related]
10. The cost of hemodialysis in a large hemodialysis center.
Al Saran K; Sabry A
Saudi J Kidney Dis Transpl; 2012 Jan; 23(1):78-82. PubMed ID: 22237223
[TBL] [Abstract][Full Text] [Related]
11. Cost analysis of dialysis treatments for end-stage renal disease (ESRD).
Goeree R; Manalich J; Grootendorst P; Beecroft ML; Churchill DN
Clin Invest Med; 1995 Dec; 18(6):455-64. PubMed ID: 8714789
[TBL] [Abstract][Full Text] [Related]
12. Establishment and maintenance of vascular access in incident hemodialysis patients: a prospective cost analysis.
Manns B; Tonelli M; Yilmaz S; Lee H; Laupland K; Klarenbach S; Radkevich V; Murphy B
J Am Soc Nephrol; 2005 Jan; 16(1):201-9. PubMed ID: 15563567
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of haemodialysis and peritoneal dialysis for patients with end-stage renal disease in Singapore.
Yang F; Lau T; Luo N
Nephrology (Carlton); 2016 Aug; 21(8):669-77. PubMed ID: 26566750
[TBL] [Abstract][Full Text] [Related]
14. Trends in patient characteristics and first-year medical costs of older incident hemodialysis patients, 1995-2005.
Mau LW; Liu J; Qiu Y; Guo H; Ishani A; Arneson TJ; Gilbertson DT; Dunning SC; Collins AJ
Am J Kidney Dis; 2010 Mar; 55(3):549-57. PubMed ID: 20116913
[TBL] [Abstract][Full Text] [Related]
15. Cost comparison of peritoneal dialysis versus hemodialysis in end-stage renal disease.
Berger A; Edelsberg J; Inglese GW; Bhattacharyya SK; Oster G
Am J Manag Care; 2009 Aug; 15(8):509-18. PubMed ID: 19670954
[TBL] [Abstract][Full Text] [Related]
16. A comparative study of renal care in Brazil and Mexico: hemodialysis treatment from the perspective of ESRD sufferers.
Mercado-Martinez FJ; da Silva DG; Correa-Mauricio ME
Nurs Inq; 2017 Apr; 24(2):. PubMed ID: 27672007
[TBL] [Abstract][Full Text] [Related]
17. Illustrating the impact of including future costs in economic evaluations: an application to end-stage renal disease care.
Manns B; Meltzer D; Taub K; Donaldson C
Health Econ; 2003 Nov; 12(11):949-58. PubMed ID: 14601157
[TBL] [Abstract][Full Text] [Related]
18. Is CAPD a viable option among ADPKD with end stage renal disease population in India? Its outcomes and economics.
Kaul A; Dharshan R; Bhadhuaria D; Prasad N; Gupta A; Sharma RK
Saudi J Kidney Dis Transpl; 2015 Sep; 26(5):906-11. PubMed ID: 26354561
[TBL] [Abstract][Full Text] [Related]
19. Economic evaluation of hemodialysis: implications for technology assessment in Greece.
Kaitelidou D; Ziroyanis PN; Maniadakis N; Liaropoulos LL
Int J Technol Assess Health Care; 2005; 21(1):40-6. PubMed ID: 15736513
[TBL] [Abstract][Full Text] [Related]
20. Cost analysis of the Hemodialysis Reliable Outflow (HeRO) Graft compared to the tunneled dialysis catheter.
Al Shakarchi J; Inston N; Jones RG; Maclaine G; Hollinworth D
J Vasc Surg; 2016 Apr; 63(4):1026-33. PubMed ID: 26826055
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
